Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
urine and blood test: 3 urine collections of an 8h period. One blood sample for liver function test and copper assessment
Study summary
Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. Patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations.
Treatment is based either on chelating the copper accumulated in the body using D-penicillamine or Trientine or on limiting intestinal copper absorption with zinc salts.
Monitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency.
Nevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. Without this, clinical decisions are usually made based on spot urine.
There is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine.
According to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon.
The study would aim to find the period of the day best correlated with 24h urinary copper excretion
Eligibility
Primary outcome measure(s)
- Correlation factor — Two 24-hour urine recollection
Correlation between 24-hour urinary copper excretion and 8-hour urinary copper excretion collected between midnight and 8 am).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Service de Gastroentérologie, Hépatologie et Nutrition Pédiatriques - Hôpital Femme Mère Enfant | Bron | Rhone | Recruiting |
More Hospices Civils de Lyon trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06430359 on ClinicalTrials.gov ↗ ← All trials in France